摘要
目的:探讨普拉克索联合多巴丝肼片治疗帕金森病的疗效及对血清脑源性神经营养因子(BDNF)、5-羟色胺(5-HT)、去甲肾上腺素(NE)的影响。方法:选择2015年6月至2017年6月我院接诊的100例帕金森病患者进行研究,通过随机数表法分为观察组(n=50)和对照组(n=50),对照组给予多巴丝肼片治疗,观察组联合普拉克索治疗,均连续治疗12周。比较两组临床疗效,应用帕金森统一评分量表(UPDRS)进行评分,应用酶联免疫吸附法检测血清BDNF、5-HT、NE和记录两组的不良反应。结果:治疗后,观察组临床疗效总有效率为94.00%(47/50),明显比对照组的76.00%(38/50)高(P<0.05);治疗后,两组UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ和UPDRS总分分值较治疗前均显著降低(P<0.05),且观察组UPDRSⅠ、UPDRSⅡ、UPDRSⅢ、UPDRSⅣ和UPDRS总分分值均明显低于对照组(P<0.05);治疗后,两组血清BDNF、5-HT、NE较治疗前均显著增加(P<0.05),且观察组血清BDNF、5-HT、NE均明显高于对照组(P<0.05);两组治疗期间恶心呕吐、嗜睡、失眠、上腹不适、视觉异常等不良反应发生率比较无显著差异(P>0.05)。结论:在帕金森病患者中应用普拉克索联合多巴丝肼片效果显著,可明显提高临床疗效,其内在机制可能和增加血清BDNF、5-HT、NE的表达相关。
Objective： To study curative efficacy of pramipexole combined with benserazide tablets in treatment of parkinson＇s disease and effects on serum brain derived neurotrophic factor（BDNF）,5-serotonin（5-HT） and norepinephrine（NE） level. Methods： 100 patients of parkinson＇s disease who received therapy from June 2015 to June 2017 in our hospital were selected as research objects,according to random number table,those patients were divided into the observation group（n = 50） and the control group（n = 50）. The control group was treated with benserazide tablets,while the observation group was combined with pramipexole.All the patients were treated continuously for 12 weeks. The clinical effects,Parkinson＇s unified score scale（UPDRS） score,serum BDNF,5-HT,NE and adverse reactions of two groups were compared. The clinical effects of two groups were compared with the Parkinson unified score scale（UPDRS）,and the enzyme linked immunosorbent assay was used to detect serum BDNF,5-HT and NE,and the adverse reactions of the two groups were recorded. Results： After treatment,the total effective rate of clinical efficacy in the observation group was 94%（47/50）,which was significantly higher than that of the control group 76%（38/50）（P 0.05）; after treatment,the scores of UPDRS I,UPDRSⅡ,UPDRS Ⅲ,UPDRS Ⅳ and UPDRS total score of two groups were significantly lower than those before treatment（P 0.05）,and the scores of UPDRS I,UPDRSⅡ,UPDRS Ⅲ,UPDRS Ⅳ and UPDRS total score in the observation group were significantly lower than that of the control group（P 0.05）; after treatment,the serum BDNF,5-HT and NE in the two groups were significantly higher than those before the treatment（P 0. 05）,and the serum BDNF,5-HT and NE in the observation group were significantly higher than that of the control group（P 0.05）; there was no significant difference in the incidence of nausea,vomiting,sleeplessness,upper abdominal discomfort and visual abnormality during the treatment of the two groups（P 0.05）. Conclusion： Pramipexole combined with benserazide tablets is well for parkinson＇s disease,which can effectively improve the clinical effect,and its internal mechanism may be related to the increase of the expression of serum BDNF,5-HT and NE.
作者
张彬彬
候宇
娄伟
ZHANG Binbin;HOU Yu;LOU Wei(The Third People＇s Hospital of Dalian,Liaoning Dalian 116033,China)
出处
《河北医学》
CAS
2018年第8期1297-1301,共5页
Hebei Medicine
基金
辽宁省科技计划项目
(编号:20110712)
关键词
帕金森病
多巴丝肼
普拉克索
Parkinson＇s disease
Benserazide
Pramipexole
